GlassScriptPhysician profile
Steven M Tate
NPI 1427045830
$1,461.59
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $167 · 2021: $436 · 2022: $497 · 2023: $19.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $493.24 | 2019-2022 | |
| Genzyme Corporation | $273.17 | 2019-2023 | |
| Alk-Abello, INC | $223.21 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $186.28 | 2019-2022 | |
| Kaleo, INC. | $76.58 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $64.54 | 2021 | |
| Glaxosmithkline, LLC. | $56.54 | 2019 | |
| Amgen INC. | $48.07 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $16.19 | 2020 | |
| Hikma Pharmaceuticals USA | $12.62 | 2022 | |
| Optinose US, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.